Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASEP Medical HoldingsXCNQ:ASEP 19 PB Ratio is 0.70 as of Jul. 25, 2026, which is 28% below its 10-year median of 0.97. GuruFocus rates XCNQ:ASEP with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 1,229 Biotechnology companies, ASEP Medical Holdings ranks better than 69.81% on this metric.
The historical rank and industry rank for ASEP Medical Holdings's PB Ratio or its related term are showing as below:
XCNQ:ASEP'
s PB Ratio Range Over the Past 10 Years
Min: 0.36 Med: 0.97 Max: 1.68
Current: 0.7
During the past 5 years, ASEP Medical Holdings's highest PB Ratio was 1.68. The lowest was 0.36. And the median was 0.97.
XCNQ:ASEP's PB Ratio is ranked better than 69.81% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs XCNQ:ASEP: 0.70
During the past 12 months, ASEP Medical Holdings's average Book Value Per Share Growth Rate was -67.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -56.20% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of ASEP Medical Holdings was -42.00% per year. The lowest was -56.20% per year. And the median was -49.10% per year.
Back to Basics: PB Ratio
ASEP Medical Holdings (XCNQ:ASEP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCNQ:ASEP vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, ASEP Medical Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ASEP Medical Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ASEP Medical Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where ASEP Medical Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ASEP Medical Holdings (XCNQ:ASEP) has a PB Ratio of 0.70 as of Jul. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ASEP Medical Holdings and its competitors. This is 28% below median its historical median of 0.97. Over the past decade, ASEP Medical Holdings' PB Ratio has ranged from 0.36 to 1.68. According to the industry distribution chart, ASEP Medical Holdings ranks #371 out of 1229 companies in the Biotechnology industry, placing it in the top 30.2%.
Is ASEP Medical Holdings' PB Ratio too high?
ASEP Medical Holdings' current PB Ratio of 0.70 is 28% below median its 10-year median of 0.97. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 1.68. The Biotechnology industry median PB Ratio is 2.79. ASEP Medical Holdings' value of 0.70 is 74.9% below this industry median. Based on the distribution chart, ASEP Medical Holdings ranks #371 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ASEP Medical Holdings has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does ASEP Medical Holdings' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ASEP Medical Holdings ranks #371 out of 1229 companies for PB Ratio. This puts ASEP Medical Holdings in the upper half of its industry. The industry median PB Ratio is 2.79. ASEP Medical Holdings' value of 0.70 is 74.9% below this benchmark. Historically, ASEP Medical Holdings' own PB Ratio has ranged from 0.36 to 1.68 over the past decade. While the company's 10-year median is 0.97 vs. the industry median of 2.79, ASEP Medical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ASEP Medical Holdings's current PB Ratio of 0.70 is 74.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ASEP Medical Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ASEP Medical Holdings's current PB Ratio is 0.70, which is 28% below median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASEP Medical Holdings stock overvalued right now?
ASEP Medical Holdings (XCNQ:ASEP) has a current PB Ratio of 0.70. The current PB Ratio is 0.70, which is 28% below median its 10-year median of 0.97 and 74.9% below the Biotechnology industry median of 2.79. ASEP Medical Holdings' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ASEP Medical Holdings (XCNQ:ASEP), the current PB Ratio is 0.70 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ASEP Medical Holdings Inc is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. Diagnostic and therapeutic solutions represent tremendous clinical and commercial potential, through rapid diagnostics and uniquely effective treatments. Its Diagnostic has developed a novel diagnostic assay for the early and rapid risk assessment of sepsis. Therapeutic offering: Patented peptide technology targets infection-causing biofilms and reduces inflammation.
19GF Score
Get the complete analysis for XCNQ:ASEP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:ASEP has been successfully added to your 
